A Phase 1 Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 (Daunorubicin and Cytarabine) Liposome for Injection Treatment in Adult Patients With Hematologic Malignancies
Principal Investigator
David SanfordOverview
Body Locations and Systems
LeukemiaDisorders and Conditions
ClinicalTrials.gov#
NCT03555955Status
RecruitingStudy Start/End
Nov 29, 2019 to Jan 31, 2021Locations
Vancouver General HospitalName/Title
Hong Li, Research CoordinatorPhone
604-875-4111 ext.52496Email Address
hong.li@bccancer.bc.caPurpose of Study
The purpose of this study is to evaluate the pharmacokinetics and safety of CPX-351 in patients with acute myeloid leukemia with moderate or severe renal impairment.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.